Category: Iridex Corp.
Iridex touts FDA and CE clearance for its TxCell scanning laser delivery system, a non-invasive device designed to treat serious retinal diseases.
Mountain View, Calif.-based Iridex (NSDQ:IRIX) is celebrating twin regulatory wins for its laser system to treat serious retinal diseases.
The company said it landed FDA clearance in the U.S. and the CE Mark in the EU for its TxCell scanning laser delivery system, which would help physicians deliver the laser in a multi-spot scanning mode for the treatment of serious retinal diseases, according to a press release.
Iridex announces the sudden departure of president & CEO Dominik Beck, the appointment of interim president, chairman & CEO William Moore, and the selection of James Mackaness as COO.
Iridex shuffles its executive deck
Elekta's Q3 sales spike, earnings soar; Essilor's 2011 sales, earnings rise; DGT's sales rise, profits soar on divestiture; Q4, 2011 sales slump, losses widen for Stereotaxis; Sales, earning slide for Iridex in Q4; Losses soar for Imris in 2011; CasMed's sales slide, losses widen for Q4, 2011; and Oridion's 2011 sales rise, profits slide.
Elekta's Q3 sales spike, earnings soar
Growth rates for the hip and knee implant market are stable but in the low-single-digit range, according to analysts who attended the American Academy of Orthopedic Surgeons last week; also, Baxter, Hill-Rom close buyouts; BioStart closes down; Medisafe 1 to launch share buyback; Solos Endoscopy retires 150m shares; Daxor backtracks, will register as investment company; and analysts' ups and downs, a deals roundup and a funding roundup.
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion's share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector's outlook calls for low-single-digit growth.
Cutera Inc. will pony up $5.1 million for Iridex Corp.'s global aesthetic business arm.
Cutera Inc. (NSDQ:CUTR) entered into a binding agreement with Mountain View, Calif.-based Iridex (NSDQ:IRIX) to purchase parts of its global aesthetic business arm for $5.1 million.
The deal is expected to advance Cutera's place in the $1 billion global aesthetic business market, expanding the company's presence in the vascular aesthetic sector while allowing Iridex room to focus on laser eye treatments.
Smith & Nephew's third-quarter profits slip on declining profit margins for its orthopedic division, sending shares down nearly 3 percent on Wall Street today.
Lower margins for Smith & Nephew's (NYSE:SNN) bread-and-butter orthopedics division drove the British company's third-quarter profits down nearly 3 percent for the three months ended Oct. 1.
Smith & Nephew posted profits of $133 million, or 14.9 cents per share, on sales of $1.03 billion for the quarter – a top-line increase of 9.7 percent when compared with the $941 million in revenues reported for the same period last year. But Q3 2010 profits were $137 million, or 15.4 cents per share.
InVivo Therapeutics appoints spinal cord injury expert Dr. Edward Wirth as its new chief scientific officer.
InVivo Therapeutics Holdings Corp. (OTC:NVIV) appointed spinal cord injury expert Dr. Edward Wirth as its new chief scientist.
InVivo brings Wirth to the team as its waiting for a green light by the FDA to begin human trials of its biodegradable scaffold for treating spinal cord injury.
The scaffold is designed to protect and support spinal tissue and prevent secondary injury, including inflammation and glial scarring, following traumatic spinal cord injury.